Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/WNO.0b013e3181fd9435 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Analyzing Secondary Cancer Risk: A Machine Learning Approach.
Asian Pac J Cancer Prev
January 2025
Department of Physics, Faculty of Sciences, Arak University, Arak, Iran.
Objective: Addressing the rising cancer rates through timely diagnosis and treatment is crucial. Additionally, cancer survivors need to understand the potential risk of developing secondary cancer (SC), which can be influenced by several factors including treatment modalities, lifestyle choices, and habits such as smoking and alcohol consumption. This study aims to establish a novel relationship using linear regression models between dose and the risk of SC, comparing different prediction methods for lung, colon, and breast cancer.
View Article and Find Full Text PDFImpact of lactate levels on admission in STEMI patients with cardiogenic shock treated with IMPELLA.
Heart Vessels
January 2025
Division of Cardiology, Mitsui Memorial Hospital, Kanda-Izumicho 1, Chiyoda-ku, Tokyo, 101-8643, Japan.
The concomitant use of IMPELLA and veno-arterial extracorporeal membrane oxygenation (V-A ECMO) (ECPELLA) has been increasingly used to treat severe cardiogenic shock. However, the relationship between severity of heart failure on admission and prognosis based on differences in the mechanical circulatory support (MCS) is not fully understood. This study evaluated the association between lactate levels on admission and clinical outcomes based on differences in MCS.
View Article and Find Full Text PDFDuration of aromatase inhibitor use and long-term cardiovascular risk in breast cancer survivors.
JNCI Cancer Spectr
January 2025
Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Background: There are limited data on duration of aromatase inhibitor (AI) and cardiovascular disease (CVD) risk in breast cancer (BC) survivors. We examined risk of CVD and mortality associated with duration of AI use in postmenopausal women with early-stage hormone receptor-positive BC.
Methods: Postmenopausal women diagnosed with hormone receptor-positive BC (n = 5,853) who used an AI were included.
Prevalence and Prognostic Impact of ST Segment Elevation in Lead aVR Among Patients with Cardiac Arrest.
Eur Heart J Acute Cardiovasc Care
January 2025
Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT.
Background: In acute coronary syndrome, ST-segment elevation in lead aVR (STE-aVR) indicates global myocardial ischemia, often related to multivessel or severe left main disease, and correlates with increased mortality. The prevalence and prognostic significance of STE-aVR in cardiac arrest (CA) patients is unknown.
Methods: We identified patients (≥18 years) with CA between 2011 to 2022 who achieved return of spontaneous circulation (ROSC).
Women Ridesharing Drivers' Responses to Sexual Violence on the Job: The Role of Confrontation.
J Interpers Violence
January 2025
Rutgers, The State University of New Jersey, New Brunswick, New Jersey, USA.
One critical area where sexual violence has been underexplored is in the ridesharing industry in the United States, where women drivers frequently must interact with unknown male passengers. Sexual violence against them is categorized as technology-facilitated gender-based violence in the online to offline world, where services such as transportation are ordered through an online app and result in a person-to-person interaction once the driver picks the passenger up. Since ridesharing drivers are mostly independent contractors, they do not have at their disposal traditional legal and strong organizational remedies to address sexual violence; moreover, like all victims of violence, these methods usually can only be accessed after the incident has taken place.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!